Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...